Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer Biomarkers

• Publication date

  2006-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3233/CBM-2006-2603PMID 17264396
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The amplified peptidome: the new treasure chest of candidate biomarkers.

  2006cited by this paper
• SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics.

  2005cited by this paper
• Application of serum SELDI proteomic patterns in diagnosis of lung cancer

  2005cited by this paper
• Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.

  2005cited by this paper
• Proteomic patterns: their potential for disease diagnosis.

  2005cited by this paper
• Classification of cancer types by measuring variants of host response proteins using SELDI serum assays

  2005cited by this paper
• Importance of communication between producers and consumers of publicly available experimental data.

  2005cited by this paper
• Prediction of Pancreatic Cancer by Serum Biomarkers Using Surface-Enhanced Laser Desorption/Ionization-Based Decision Tree Classification

  2005cited by this paper
• Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells.

  2005cited by this paper
• Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer.

  2005cited by this paper
• Clinical proteomics: Applications for prostate cancer biomarker discovery and detection.

  2004cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004cited by this paper
• Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.

  2004cited by this paper
• Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.

  2004cited by this paper
• Diagnosis of pancreatic cancer using serum proteomic profiling.

  2004cited by this paper
• SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer.

  2004cited by this paper
• Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems.

  2004cited by this paper
• The Human Plasma Proteome: History, Character, and Diagnostic Prospects

  2003cited by this paper
• Putative protein markers in the sera of men with prostatic neoplasms

  2003cited by this paper
• Counterpoint: The vision for a new diagnostic paradigm.

  2003cited by this paper
• Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics?

  2003cited by this paper
• The Vision for a New Diagnostic Paradigm

  2003cited by this paper
• Serum proteomic patterns for detection of prostate cancer.

  2002cited by this paper
• Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients.

  2002cited by this paper
• Recent advancements in surface‐enhanced laser desorption/ionization‐time of flight‐mass spectrometry

  2000cited by this paper
• Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

  2000cited by this paper
• Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

  1999cited by this paper
• Identification of needs in biomarker research.

  1996cited by this paper
• Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the european organization for research and treatment of cancer–‐genitourinary group study 30853

  1993cited by this paper
• A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

  1989cited by this paper
• Cancer statistics

  1989influential reference

• A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification.

  2015cites this paper
• Identification of PTHrP(12-48) as a Plasma Biomarker Associated with Breast Cancer Bone Metastasis

  2013influential citation
• Oral glutamine reduces radiation morbidity in breast conservation surgery.

  2013cites this paper
• Identi fi cation of PTHrP ( 1248 ) as a Plasma Biomarker Associated with Breast Cancer Bone Metastasis

  2013cites this paper
• Detection and prognostic analysis of serum protein expression in esophageal squamous cell cancer.

  2012cites this paper
• Cancer Biomarkers for Diagnosis, Prognosis and Therapy

  2012cites this paper
• The Application of SELDI-TOF-MS in Clinical Diagnosis of Cancers

  2011cites this paper
• Metastasis: new perspectives on an old problem

  2011cites this paper
• Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis.

  2010cites this paper
• Innovative biomarkers for prostate cancer early diagnosis and progression.

  2010cites this paper
• Evolving role of bone biomarkers in castration-resistant prostate cancer.

  2010cites this paper
• Proteomics of Bone Cancer

  2010cites this paper
• The promise of bone cancer proteomics

  2010cites this paper
• Proteomics and cancer epidemiology.

  2009cites this paper
• A comparative study on proteomics between LNCap and DU145 cells by quantitative detection and SELDI analysis

  2008cites this paper
• Influence of variations in sample handling on SELDI‐TOF MS serum protein profiles for colorectal cancer

  2008cites this paper
• Proteomics of cancer of hormone-dependent tissues.

  2008cites this paper
• A comparative study on proteomics between LNCap and DU145 cells by quantitative detection and SELDI analysis

  2008cites this paper
• Serum Biomarker Profile Associated With High Bone Turnover and BMD in Postmenopausal Women

  2008cites this paper
• Proteomic analysis of bone cancer: a review of current and future developments

  2007cites this paper
• Proteomics in clinical prostate research

  2007cites this paper
• RESEARCH COMMUNICATION Detection and Prognostic Analysis of Serum Protein Expression in Esophageal Squamous Cell Cancer

  year unknowncites this paper